Annoviant™ Awarded $2.99 Million NIH Grant to Advance TxGuard™ Pulmonary-Valved Conduit for Pediatric Heart Disease

Posted on by

ATLANTA, April 16, 2024 /PRNewswire/ — Annoviant™, Inc., a pioneering company with a breakthrough TxGuard™ technology platform for soft-tissue healing, currently focused on cardiovascular field, proudly announces receipt of a $2.99 million grant (SBIR Phase 2b) from the National…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.